Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer

References

• Xu R, Zhang Y, Ye X, et al. Inhibition effects and induction of apoptosis of flavonoids on the prostate cancer cell line PC-3 in vitro. Food Chem 2013;138:48–53
   PubMed Web of Science ®Google Scholar
• Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013;39:275–89
   PubMed Web of Science ®Google Scholar
• Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM. Hsp90: still a viable target in prostate cancer. Biochim Biophys Acta 2013;1835:211–18
   PubMed Web of Science ®Google Scholar
• Duan S, Bleibel WK, Huang RS, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007;67:5425–33
   Google Scholar
• Chang YJ, Huang YP, Li ZL, Chen CH. GRP78 knockdown enhances apoptosis via the down-regulation of oxidative stress and akt pathway after epirubicin treatment in colon cancer DLD-1 cells. PLoS One 2012;7:e35123
   PubMed Web of Science ®Google Scholar
• Petrioli R, Fiaschi AI, Pozzessere D, et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 2002;87:720–5
   PubMed Web of Science ®Google Scholar
• Petrioli R, Fiaschi AI, Francini E, et al. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev 2008;34:710–18
   PubMed Web of Science ®Google Scholar
• Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2007;2:219–32
   PubMed Web of Science ®Google Scholar
• Jain KK. Editorial: targeted drug delivery for cancer. Technol Cancer Res Treatment 2005;4:311–13
   PubMed Web of Science ®Google Scholar
• Li DC, Zhong XK, Zeng ZP, et al. Application of targeted drug delivery system in Chinese medicine. J Control Release 2009;138:103--12
   PubMed Web of Science ®Google Scholar
• Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Inter Edit 2006;45:8149–52
   PubMed Web of Science ®Google Scholar
• Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 2009;10:862–8
   PubMed Web of Science ®Google Scholar
• Taghdisi SM, Abnous K, Mosaffa F, Behravan J. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J Drug Target 2010;18:277–81
   PubMed Web of Science ®Google Scholar
• Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Inter Edit 2009;48:6494–8
   PubMed Web of Science ®Google Scholar
• Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008;26:442–9
   PubMed Web of Science ®Google Scholar
• Stoltenburg R, Reinemann C, Strehlitz B. SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007;24:381–403
   PubMedGoogle Scholar
• Davis KA, Lin Y, Abrams B, Jayasena SD. Staining of cell surface human CD4 with 2′-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucl Acids Res 1998;26:3915–24
   PubMed Web of Science ®Google Scholar
• Cerchia L, Duconge F, Pestourie C, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005;3:e123
   PubMed Web of Science ®Google Scholar
• Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Therapy 2007;14:283–91
   PubMed Web of Science ®Google Scholar
• Blank M, Blind M. Aptamers as tools for target validation. Curr Opin Chem Biol 2005;9:336–42
   PubMed Web of Science ®Google Scholar
• Cerchia L, Esposito CL, Camorani S, et al. Coupling aptamers to short interfering RNAs as therapeutics. Pharmaceuticals 2011;4:1434–49
   Google Scholar
• Meyer C, Hahn U, Rentmeister A. Cell-specific aptamers as emerging therapeutics. J Nucleic Acids 2011;2011:904750
   PubMedGoogle Scholar
• Bagalkot V, Zhang L, Levy-Nissenbaum E, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer. Nano Lett 2007;7:3065–70
   PubMed Web of Science ®Google Scholar
• Ray P, White RR. Aptamers for targeted drug delivery. Pharmaceuticals 2010;3:1761–78
   Google Scholar
• Tan L, Neoh KG, Kang ET, et al. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol Biosci 2011;11:1331–5
   PubMed Web of Science ®Google Scholar
• Banerjee SS, Aher N, Patil R, Khandare J. Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. J Drug Deliv 2012;2012:103973
   PubMedGoogle Scholar
• Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 2008;105:17356–61
   PubMed Web of Science ®Google Scholar
• Erdem A, Ozsoz M. Interaction of the anticancer drug epirubicin with DNA. Anal Chim Acta 2001;437:107–14
   Web of Science ®Google Scholar
• Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treatment 2005;4:363–74
   PubMed Web of Science ®Google Scholar
• Zhu L, Huo Z, Wang L, et al. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharmaceutics 2009;370:136–43
   PubMed Web of Science ®Google Scholar
• Ye X, Yang D. Recent advances in biological strategies for targeted drug delivery. Cardiovasc Hematol Disorders – Drug Targets 2009;9:206–21
   PubMedGoogle Scholar
• Taghdisi SM, Lavaee P, Ramezani M, Abnous K. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. Eur J Pharm Biopharm 2011;77:200–6
   PubMed Web of Science ®Google Scholar
• Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010;9:537–50
   PubMed Web of Science ®Google Scholar
• Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010;50:237–57
   PubMed Web of Science ®Google Scholar
• Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011;6:715–28
   PubMed Web of Science ®Google Scholar
• Pai SS, Tilton RD, Przybycien TM. Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J 2009;11:88–98
   PubMed Web of Science ®Google Scholar